Immunosuppressant | N (%) of cohort treated | Duration of therapy | Achieved CR (N) | Relapsed (N) | Time to relapse (months) |
|---|
Calcineurin inhibitors | 25 (32) | 18 (10–34)a | 21 | 16 | 7 (2–22) |
Cyclophosphamide | 10 (13) | 9 (8–10)b | 9 | 6 | 20 (5–44) |
Levamisole | 7 (9) | 7 (4–38)b | 6 | 5 | 10 (3–14) |
Mycophenolate mofetil | 6 (8) | 10 (3–29)a | 4 | 3 | 47 (25–56) |
Rituximab | 4 (5) | N/A | 4 | 0 | N/A |
- The table shows the number (percentage) of the total cohort treated with each class of immunosuppressant, with the median (IQR) duration of the course, and the number who achieved complete remission. The number who went on to relapse is shown, with the median (IQR) time to relapse. Cyclophosphamide was given orally in all cases. If a patient received more than one course of a particular class of agent, the median therapy duration of therapy and the remission/relapse rates relate to the first course given. amonths; bweeks
